Highlights of This Issue 2283

SMALL MOLECULE THERAPEUTICS

Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Yang Xiao, Judi Ramiscal, Kaska Kowanetz, Christopher Del Nagro, Shiva Malek, Marie Evangelista, Elizabeth Blackwood, Peter K. Jackson, and Thomas O’Brien 2356

Gramicidin A Induces Metabolic Dysfunction and Energy Depletion Leading to Cell Death in Renal Cell Carcinoma Cells
Justin M. David, Tori A. Owens, Sonali P. Barwe, and Ayyappan K. Rajasekaran 2367

Developing Lipid Nanoparticle-Based siRNA Therapeutics for Hepatocellular Carcinoma Using an Integrated Approach
Leiming Li, Rongqi Wang, Denise Wilcox, Aparna Sarthy, Xiaoyu Lin, Xiaoli Huang, Lu Tian, Prasad Dane, Robert D. Hubbard, Todd M. Hansen, Jieyin Lui, Chao Yang, Dmitri Kireev, Catherine Simpson, Jacqueline Norris-Drouin, Emily A. Hull-Ryde, William M. Kohlbrenner, and Douglas K. Graham 2378

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu, Bruce R. Rowley, Cathy O. Bull, Claudia Schneider, Andrea Haegebarth, Christoph A. Schatz, Paul R. Fracasso, Dean P. Wilkie, Martin Hentemann, Scott M. Wilhelm, William J. Scott, Dominik Mumberg, and Karl Ziegelbauer 2389

PRIMA-1met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Manujendra N. Saha, Hua Jiang, Yijun Yang, Donna Reeco, and Hong Chang 2400

Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Christian Thomas, Francois Lamoureux, Claire Crafter, Barry R. Davies, Eliana Beraldi, Ladan Fazli, Soojin Kim, Daksh Shaper, Martin E. Gleave, and Amina Zoubeidi 2432

AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo
Sandra Christoph, Deborah DeRyckere, Jennifer Schlegel, J. Kimble Frazer, Lance A. Batchelor, Ayyappan K. Rajasekaran, Christopher T. Cummings, Jing Liu, Gary L. Johnson, Xiaodong Wang, Stephen V. Frye, and Christopher M. Trails 2441

SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Takeshi Masuda, Noboru Hattori, Tasahori Senoo, Shin Akita, Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, and Nobuo Kohno 2442

Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model
Rajendar K. Mittapalli, Xinli Liu, Chris E. Adkins, Mohamed I. Nounou, Kaci A. Bohn, Tori B. Terrell, Hussaini S. Qhattal, Werner J. Geldenhuys, Diane Palmieri, Patricia S. Steeg, Quentin R. Smith, and Paul R. Lockman 2443

Isolation of a Novel Thioflavin S–Derived Compound That Inhibits BAG-1–Mediated Protein Interactions and Targets BRAF Inhibitor–Resistant Cell Lines
Marion Enthammer, Emmanouil S. Papadakis, Maria Salome Gachet, Martin Deutsch, Stefan Schweiger, Katarzyna Koziel, Muhammad Imtiaj Ashraf, Sana Khalid, Gerhard Wolber, Graham Packham, Ramsey I. Cutress, Hermann Stuppner, and Jakob Troppmair 2444
miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Gang Zhao, Bo Wang, Yang Liu, Jun-gang Zhang, Shi-chang Deng, Qi Qin, Kui Tian, Xiang Li, Shuai Zhu, Yi Niu, Qiong Gong, and Chun-you Wang

Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
Yan Long, Wen-Bin Tsai, Medhi Wangpaichitr, Takashi Tsukamoto, Niramol Savaraj, Lynn G. Feun, and Macus Tien Kuo

Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Hae-June Lee, Changhwan Yoon, Benjamin Schmidt, Do Joong Park, Alexia Y. Zhang, Hayriye V. Erkizan, Jeffrey A. Toretsky, David G. Kirsch, and Sam S. Yoon

Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non-Small Cell Lung Cancer

EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter
Pei Jye Voon, Dana Wai Yi Tsui, Nitzan Rosenfeld, and Tan Min Chin

Tools and Technologies

ABOUT THE COVER

Ribbon representation of a homology model of the c-Met specific Anticalin PRS-110. Anticalins are engineered human lipocalins that represent a next generation class of drug molecules. The lipocalins have a structurally conserved β-barrel architecture that forms a cup-shaped ligand binding pocket that can accommodate small and large ligands. The β strands (blue) of the lipocalin form the base of the ligand-binding pocket and the entry of the pocket is comprised of four loops connecting the β strands. Novel, target-specific Anticalins are generated by engineering mutations (pink regions, PRS-110 mutations) within these four loops and then selecting variants with the desired binding activity. For details, see article by Olwill and colleagues on page 2459.

For more information please visit www.aacrjournals.org
Molecular Cancer Therapeutics

12 (11)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/12/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.